CYP2C9 ACTIVITY IN TURKISH PATIENTS WITH RHEUMATOID ARTHRITIS

被引：0
|
作者：
Ozer, E. K. [1 ]
Albayrak, I. [2 ]
Goktas, M. T. [3 ]
机构：
[1] Selcuk Univ, Fac Med, Dept Pharmacol, Konya, Turkey
[2] Selcuk Univ, Fac Med, Dept Phys Med & Rehabil, Konya, Turkey
[3] Yildirim Beyazit Univ, Fac Med, Dept Pharmacol, Ankara, Turkey
来源：
ANNALS OF THE RHEUMATIC DISEASES | 2016年 / 75卷
关键词：
D O I：
10.1136/annrheumdis-2016-eular.2259
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
AB0200
引用
收藏
页码：965 / 966
页数：2
相关论文
共 50 条
  • [1] Warfarin resistance with poor CYP2C9 activity and CYP2C9*1*2 genotype
    Dericioglu, N
    Babaoglu, MO
    Saygi, S
    Bozkurt, A
    Yasar, U
    ANNALS OF PHARMACOTHERAPY, 2004, 38 (05) : 899 - 899
  • [2] CYP2C9 polymorphisms and CYP2C9*2 genotyping primers
    Goldstein, JA
    BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 2002, 53 (04) : 409 - 410
  • [3] Significance of CYP2C9 genetic polymorphism in inhibitory effect of Δ9-tetrahydrocannabinol on CYP2C9 activity
    Satoshi Yamaori
    Mika Kushihara
    Kyoko Koeda
    Ikuo Yamamoto
    Kazuhito Watanabe
    Forensic Toxicology, 2013, 31 : 70 - 75
  • [4] Significance of CYP2C9 genetic polymorphism in inhibitory effect of Δ9-tetrahydrocannabinol on CYP2C9 activity
    Yamaori, Satoshi
    Kushihara, Mika
    Koeda, Kyoko
    Yamamoto, Ikuo
    Watanabe, Kazuhito
    FORENSIC TOXICOLOGY, 2013, 31 (01) : 70 - 75
  • [5] Role of CYP2C9 and its variants (CYP2C9*3 and CYP2C9*13) in the metabolism of lornoxicam in humans
    Guo, YJ
    Zhang, YF
    Wang, Y
    Chen, XY
    Si, DY
    Zhong, DF
    Fawcett, JP
    Zhou, H
    DRUG METABOLISM AND DISPOSITION, 2005, 33 (06) : 749 - 753
  • [6] Kinetic analysis of fluvastatin metabolism by CYP2C9 and its allelic variants, CYP2C9*2 and CYP2C9*3
    Einolf, HJ
    Fischer, V
    DRUG METABOLISM REVIEWS, 2003, 35 : 191 - 191
  • [7] Catalytic roles of CYP2C9 and its variants (CYP2C9*2 and CYP2C9*3) in lornoxicam 5′-hydroxylation
    Iida, I
    Miyata, A
    Arai, M
    Hirota, M
    Akimoto, M
    Higuchi, S
    Kobayashi, K
    Chiba, K
    DRUG METABOLISM AND DISPOSITION, 2004, 32 (01) : 7 - 9
  • [8] Effect of atorvastatin on CYP2C9 metabolic activity in hypercholesterolemic patients
    Babaoglu, Melih O.
    Yasar, Umit
    Yardimci, Yildiz
    Kilicaslar, Alpaslan
    Sain-Guven, Gulay
    Bozkurt, Atila
    FASEB JOURNAL, 2007, 21 (06): : A1185 - A1185
  • [9] THE INFLUENCE OF FLUCONAZOLE AND CYP2C9*3 ON CYP2C9 ACTIVITY, ASSESSED VIA LOSARTAN URINARY RATIO
    Anikin, G. S.
    Sychev, D. A.
    Ramenskaya, G., V
    Savchenko, A. Y.
    Ignatiev, I., V
    Dmitriev, V. A.
    Kukes, V. G.
    BASIC & CLINICAL PHARMACOLOGY & TOXICOLOGY, 2011, 109 : 153 - 153
  • [10] Safety of voriconazole in a patient with CYP2C9*2/CYP2C9*2 genotype
    Geist, Marcus J. P.
    Egerer, Gerlinde
    Burhenne, Juergen
    Mikus, Gerd
    ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2006, 50 (09) : 3227 - 3228
12345